Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy 2024-04-24 15:00
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure 2024-03-19 19:09
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³ 2024-02-13 14:21
Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment 2023-11-24 15:00
CSL Signs Renewable-Linked Power Purchase Agreement with AGL to Supply Electricity to Australian Manufacturing Sites 2023-10-12 05:00
Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines 2023-08-28 19:00
Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure 2023-06-05 21:00
Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis 2023-05-03 00:22
Tavneos® (avacopan) included in updated EULAR recommendations for the management of AAV 2023-03-28 13:00
Tavneos® (avacopan) approved in Australia for the treatment of ANCA-associated vasculitis 2023-02-07 06:00
CSL Announces Next CEO & Managing Director 2022-12-13 07:23
1